Fundraising Fox
Adaptive Biotechnologies
NASDAQ: ADPTUnicorn · $3.3BSeattle, US · Founded 2009 · Washington corporation · 653 employees on LinkedIn · 5 known investors
Find your way into Adaptive Biotechnologies
2,150 people in our graph share verified history with the Adaptive Biotechnologies team — schools, employers, funds. One of them is your warm intro.
Walter Robbunlockedknows Francis Lo · together at Whole Foods Market (overlapped)
knows the team · via Fred Hutch
×4knows the team · via Starbucks
×2knows the team · via ZS Associates
knows the team · via AstraZeneca
×2knows the team · via Pepsico
Adaptive Biotechnologies applies the genetics of the adaptive immune system to diagnostics and therapeutics, translating immune-system data into clinical insights for clinicians and biopharma companies. Its Immune Medicine Platform is used to detect, monitor, and treat disease.
Founders & leadership
Adaptive Biotechnologies was founded in 2009 by Chad Robins and Harlan Robins.
CR
Chad RobinsCEO & Co-FounderHe co-founded Adaptive Biotechnologies in 2009 and also co-founded medical device company Aortica Corporation, serving on its board until 2019. His other roles include chairman of AltPep, lead independent director at HeadLight, and board chair of Life Science Washington, where he has served as a director since 2017.
HR
Harlan RobinsCo-founder; Chief Scientific Officer until 2026Harlan Robins co-founded Adaptive Biotechnologies and Harell Data, a cloud services company supporting scientific communities. He previously held roles in the Computational Biology Program at the Fred Hutchinson Cancer Research Center, including Full Member and program head, and holds a BS in Physics from Harvard and a master's and PhD in Physics from UC Berkeley, with postdoctoral work at the Weizmann Institute of Science and the Institute for Advanced Study in Princeton.
KD
Kathleen DetermannGeneral Counsel, Corporate Secretary, Privacy Officer2014–2016Executive Officer of Adaptive Biotechnologies, which applies adaptive immune system genetics to develop diagnostics and therapeutics for disease detection, monitoring, and treatment.
CC
Chris CarlsonExecutive
SB
Sharon BenzenoChief Commercial Officer, Immune MedicineSharon Benzeno is Chief Commercial Officer of Adaptive Biotechnologies, which applies adaptive immune-system genetics to diagnostics and therapeutics. She has more than 20 years of experience in pharmaceutical and biotechnology management, with expertise in cancer biology, immunology, and cell and gene therapies.
SB
Susan BobulskyChief Commercial Officer, MRDSusan Bobulsky is Chief Commercial Officer of MRD at Adaptive Biotechnologies, where she leads commercialization of the company's immune diagnostics platform. She has held both operating and strategy roles in biotechnology and diagnostics.
FL
Francis LoChief People OfficerFrancis Lo is Chief People Officer at Adaptive Biotechnologies, which applies adaptive immune system genetics to develop diagnostics and therapeutics for disease detection, monitoring, and treatment.
Board
AL
Arnold LevineBoard director
AZ
Andris ZoltnersBoard director
Investors · 5
Decheng Capitallisted by Decheng CapitalMenlo Park
How we know: Decheng Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Foresite Capitallisted by Foresite CapitalWest Hollywood
How we know: Foresite Capital's portfolio page · Not right? Tell us
Khosla Ventureslisted by Khosla VenturesMenlo Park · $5K – $50M
How we know: Khosla Ventures's portfolio page · Not right? Tell us
OrbiMedreportedNew York · $1M – $75M
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$492.6M disclosed across 5 rounds · 2014–2017
▶$195.1MraisedMay 2015 · 16 investors · BiotechnologyRule 506(b)
▶$195.1MraisedMay 2015 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter NeupertDirector
- Andris ZoltnersDirector
- Tom WillisDirector
- Kathleen DetermannExecutive Officer
- Chad RobinsExecutive Officer, Director
- Rob HershbergDirector
- Dean SchornoExecutive Officer
- John StuelpnagelDirector
- Rob RosenDirector
- Chad CohenDirector
- Arnold LevineDirector
- Offering amount
- $195.1M
- Amount sold
- $195.1M
- First sale
- May 2015
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$93.8MraisedJan 2015 · 4 investors · BiotechnologyRule 506(b)
▶$93.8MraisedJan 2015 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rob RosenDirector
- John StuelpnagelDirector
- Chad RobinsExecutive Officer, Director
- Kathleen DetermannExecutive Officer
- Peter NeupertDirector
- Lee HuntsmanDirector
- Dean SchornoExecutive Officer
- Arnold LevineDirector
- Rob HershbergDirector
- Tom WillisDirector
- Andris ZoltnersDirector
- Offering amount
- $93.8M
- Amount sold
- $93.8M
- First sale
- Jan 2015
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$95.7MraisedJan 2015 · 61 investors · BiotechnologyRule 506(b)
▶$95.7MraisedJan 2015 · 61 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Arnold LevineDirector
- Chad RobinsExecutive Officer, Director
- Andris ZoltnersDirector
- Tom WillisDirector
- Kathleen DetermannExecutive Officer
- Peter NeupertDirector
- John StuelpnagelDirector
- Lee HuntsmanDirector
- Rob HershbergDirector
- Rob RosenDirector
- Dean SchornoExecutive Officer
- Offering amount
- $95.7M
- Amount sold
- $95.7M
- First sale
- Jan 2015
- Incorporated
- Corporation, Washington
- Federal exemptions
- 06b
▶$107MraisedAug 2014 · 6 investors · BiotechnologyRule 506(b)
▶$107MraisedAug 2014 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Harlan RobinsExecutive Officer
- Rob HershbergDirector
- Lee HuntsmanDirector
- Rob RosenDirector
- Chris CarlsonExecutive Officer
- Peter NeupertDirector
- Chad RobinsExecutive Officer, Director
- Arnold LevineDirector
- Andris ZoltnersDirector
- Offering amount
- $107M
- Amount sold
- $107M
- First sale
- Apr 2014
- Incorporated
- Corporation, Washington, 2009
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$3.3Bvaluation at IPOJan 2020 · $26.50/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
3 people who came through Adaptive Biotechnologies went on to found or lead other companies.
Frequently asked questions
- What does Adaptive Biotechnologies do?
- Adaptive Biotechnologies applies the genetics of the adaptive immune system to diagnostics and therapeutics, translating immune-system data into clinical insights for clinicians and biopharma companies. Its Immune Medicine Platform is used to detect, monitor, and treat disease.
- Who founded Adaptive Biotechnologies?
- Adaptive Biotechnologies was founded by Chad Robins, Harlan Robins in 2009.
- Who are Adaptive Biotechnologies's investors?
- Adaptive Biotechnologies's investors include Decheng Capital, FMG Capital, Foresite Capital, Khosla Ventures, OrbiMed.
- How much funding has Adaptive Biotechnologies raised?
- Adaptive Biotechnologies has disclosed $492.6M raised across 5 rounds.
- Where is Adaptive Biotechnologies headquartered?
- Adaptive Biotechnologies is headquartered in Seattle, US.